MedGenome

MedGenome MedGenome is a global genomics diagnostics company and home to South Asia’s largest CAP-accredited genetic testing lab.

With 1300+ tests across oncology, rare diseases, reproductive health and more, we support accurate diagnosis and better patient care. MedGenome is a global genomics and precision diagnostics company focused on enabling accurate, early and actionable diagnosis through advanced genomic science. We operate South Asia’s largest CAP-accredited genetic testing laboratory and offer a comprehensive test menu of more than 1,300 genetic assays across key disease areas. Our diagnostic capabilities span rare inherited disorders, oncology, reproductive health, infectious diseases and preventive wellness. By integrating next-generation sequencing technologies with proprietary assays and AI-enabled bioinformatics platforms, MedGenome delivers high-quality genomic insights that support clinicians in complex clinical decision-making. Founded with a vision to make genomic healthcare affordable and accessible, MedGenome has built deep scientific and clinical expertise backed by extensive research and global collaborations. Our work is supported by a strong research foundation with hundreds of peer-reviewed scientific publications, reflecting our commitment to evidence-based diagnostics and innovation. MedGenome serves clinicians and healthcare institutions across hundreds of locations in India and multiple countries worldwide. Our team of scientists, genome analysts, bioinformaticians and clinical experts works closely with healthcare providers to ensure test accuracy, clinical relevance and timely reporting. We are driven by a commitment to continuous innovation, quality and education. From developing in-house genomics solutions to advancing awareness around genetic testing, MedGenome plays an active role in shaping the future of precision medicine. At MedGenome, every genome decoded strengthens our mission to improve patient outcomes, support clinicians with reliable insights and transform healthcare through the power of genomics.

28/02/2026

When something is rare, the journey can feel isolating.
For many families, the hardest part is not just the symptoms, but the uncertainty. The unanswered questions. The years of searching.
This Rare Disease Day, MedGenome stands with every patient and every family navigating that path. MedGenome’s advanced genomic diagnostics can help uncover the underlying genetic cause, bringing clarity, direction, and a starting point for care.

Because rare does not mean alone. And it should never mean invisible.

To know more: 🌐https://diagnostics.medgenome.com/rare-inherited-disorders/ or 📞 1800 296 9696

27/02/2026



Awareness, accessibility, and affordability are critical to enable genomics-led cancer care in India.

Ramprasad, PhD, CEO of MedGenome, shares that stakeholders, including the government, healthcare companies, and organizations, are actively working to enhance knowledge and access to genetic testing, improving early disease detection, and reducing the disease burden in the country.

Explore how the challenges to the widespread adoption of genetic testing are being addressed, paving the way for genomics-led, precision cancer care in India.

Watch the full video here: https://www.youtube.com/watch?v=Lcu1vsdBMtQ&t=13s

25/02/2026



Genomics is transforming cancer care today, in two crucial ways – early diagnosis and targeted treatments.

Vedam Ramprasad, CEO of MedGenome, highlights that genomics enables early detection of genetic mutations linked to cancer. This allows for timely medical interventions like regular monitoring and managing lifestyle habits that could trigger the disease. It also helps clinicians identify the precise gene mutation and tailor treatment plans targeted toward the exact mutation.

Learn how genomics is enhancing clinical processes and improving patient outcomes. Watch the full

video here: https://www.youtube.com/watch?v=Lcu1vsdBMtQ&t=13s

When time is critical, precision matters.Join our webinar to discover how NGS-based cell-free DNA metagenomics is transf...
24/02/2026

When time is critical, precision matters.
Join our webinar to discover how NGS-based cell-free DNA metagenomics is transforming bloodstream infection diagnostics with MetaSeq (powered by DISQVER®).
Hear from leading experts and participate in an interactive Q&A.

🗓 3 March 2026 | 7:30 PM (IST)

Register today to secure your seat: https://us02web.zoom.us/webinar/register/WN_Zi7NwCXGQ4-2of7u94bniw

Proud to have been a part of Race for 7, running with purpose, running for awareness   Our team at MedGenome joined hand...
23/02/2026

Proud to have been a part of Race for 7, running with purpose, running for awareness

Our team at MedGenome joined hands with ORDI at this powerful initiative dedicated to raising awareness for rare diseases. Every stride was a reminder that science, compassion, and community together can create lasting impact.
Here’s to supporting the rare, the resilient, and the hopeful.

18/02/2026

For many Indian women, genetic risks of breast and ovarian cancers are quietly passed down through generations. Genetic testing reveals this inherited risk early, giving families a chance to monitor their health, plan preventive measures, and take proactive steps in time.
MedGenome delivers for you and your family, offering hope for a healthier future.

To know more: 🌐https://diagnostics.medgenome.com/oncology/ or 📞 1800 296 9696

Learn More: 🌐https://tinyurl.com/ykk2wtwu or 📞1800 296 9696Stomach cancer continues to be among the most diagnosed cance...
16/02/2026

Learn More: 🌐https://tinyurl.com/ykk2wtwu or 📞1800 296 9696

Stomach cancer continues to be among the most diagnosed cancers globally. Within it, a rarer subtype, Gastrointestinal Stromal Tumor (GIST), often goes unnoticed due to overlapping symptoms and genetic complexity.

MedGenome’s GIST Panel helps identify critical mutations and guides clinicians with evidence-based insights as per NCCN guidelines.

11/02/2026


A family history of cancer translates to a significantly increased risk of the disease for a person, making early risk assessment an important part of preventive care.

Speaking to India Today TV, Vedam Ramprasad, PhD, CEO of MedGenome, explains that certain gene mutations linked to cancer can be inherited across generations. Genomic testing helps identify these markers, enabling a better understanding of the risk and informed measures toward surveillance and early intervention for individuals and families.

Discover how mutations in genes affect generations in a family. Watch the full video here: https://www.youtube.com/watch?v=Lcu1vsdBMtQ&t=13s

Epilepsy is not just a condition; it’s a spectrum shaped by genetics, biology, and early risk factors. With nearly 50 mi...
09/02/2026

Epilepsy is not just a condition; it’s a spectrum shaped by genetics, biology, and early risk factors. With nearly 50 million people affected worldwide, understanding the genetic basis of epilepsy syndromes is key to earlier diagnosis, precise classification, and personalised care.

This International Epilepsy Day, the focus is on moving beyond symptoms to uncover underlying genetic causes through advanced testing and expert counselling, because clarity can change outcomes, and early insights can protect lives.

To know more: 🌐https://diagnostics.medgenome.com/rare-inherited-disorders/neuro-genetic-testing/ or 📞1800 296 9696

Run for rare disease awareness. Run for impact. 🏃‍♂️MedGenome is proud to be the Diagnostic Partner for the Race For Rar...
06/02/2026

Run for rare disease awareness. Run for impact. 🏃‍♂️

MedGenome is proud to be the Diagnostic Partner for the Race For Rare 7K & 10K Timed Run in Bengaluru on 22nd February 2026. Every step you take supports better diagnosis, stronger advocacy, and lasting care for those living with rare diseases.

Lace up, show up, and be part of something bigger than a finish line. 💙

👉 Click to register now and join the movement: https://registration.racefor7.com/

06/02/2026

Despite the high burden of cancer in India, nearly 70% cases are diagnosed at advanced stages, impacting treatment outcomes. In conversation with Sneha Mordani on India Today TV, Vedam Ramprasad, PhD, CEO of MedGenome, highlights the key reasons behind this – lack of awareness around early symptoms and the importance of preventive screening.

Learn what leads to delayed diagnosis and how it affects cancer treatment. Watch the full video here: https://www.youtube.com/watch?v=Lcu1vsdBMtQ&t=13s

04/02/2026

Cancer may share a name, but no two cancers are the same, and no two patients are either. Genetic testing helps uncover what makes each cancer unique, so its treatment can be precise, personal, and effective.

This World Cancer Day, we’re in the pursuit of and better patient outcomes.

Join MedGenome in the fight against cancer. Visit medgenome.com or call 1800 296 9696 to learn more.

Address

MedGenome Labs Ltd. Sy. Nos. 94/1C And 94/2, Tower 1, Ground Floor, Veerasandra Village, Attibele Hobli, Electronic City Phase-1, Electronics City
Bangalore
560100

Opening Hours

Monday 9am - 6pm
Tuesday 9am - 6pm
Wednesday 9am - 6pm
Thursday 9am - 6pm
Friday 9am - 6pm

Telephone

+9118001033691

Alerts

Be the first to know and let us send you an email when MedGenome posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MedGenome:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category